-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Today, eGenesis, which is committed to developing organs, tissues and cells compatible with humans, announced that it has completed a $125 million Series C financing.
Currently, the demand for life-saving organs far exceeds the available supply.
eGenesis was co-founded by Professor George Church of the Massachusetts Institute of Technology (MIT) and Dr.
eGenesis is committed to solving the above problems and developing organs, tissues and cells compatible with humans.
▲eGenesis's R&D pipeline (picture source: eGenesis's official website)
Mr.
Reference materials:
[1] eGenesis Announces $125 Million Series C Financing.